| OPPOSITION | - Brandon Carl, John Tooze, "The Building Blocks", Introduction to Protein Structus Second Edition, (19990101), pages 16 - 47, XP093259529 | - |
| OPPOSITION | - Catherine S. et al. Manno, "Successful transduction of liver hemophilia by AAV-Factor IX and limitations imposed by the host immune response", Nature Medicine, (2006), vol. 12, page 3, XP002578131 | - |
| OPPOSITION | - D07: Copy of Dr. Pedersen declaration filed in opposition proceedings against EP3581650 | - |
| OPPOSITION | - D12: Copy of Dr. Wang declaration filed in opposition proceedings against EP3581650 | - |
| OPPOSITION | - D34: Database EMBL (1986) ‘Human coagulation factor IX gene, complete cds | - |
| OPPOSITION | - D59: Opposition statement against EP3581650 | - |
| OPPOSITION | - D60: Letter dated 8 July 2024 filed in EP3581650 opposition proceed | - |
| OPPOSITION | - D61 - Opposition Division's preliminary opinion from EP3581650 B1 opposition procedure | - |
| OPPOSITION | - Graham J B et al, "The Malmö polymorphism of coagulation factor IX, an immunologic polymorphism due to dimorphism of residue 148 that is in linkage disequilibrium with two other F.IX polymorphisms", American journal of human genetics, United States, United States, (19880401), pages 573 - 580, American journal of human genetics, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1715231/pdf/ajhg00127-0049.pdf, (20220616), XP055932218 | - |
| OPPOSITION | - Greenberg Daniel L., Earl W. Davie, "THE BLOOD COAGULATION FACTORS: THEIR COMPLEMENTARY DNAS, GENES, AND EXPRESSION", HEMOSTASIS AND THROMBOSIS Basic Principles and Clinical Practice, CHAPTER 3, (20060101), pages 21 - 57, XP093259715 | - |
| OPPOSITION | - KOTOKU KURACHI; EARL W. DAVIE, "Isolation and characterization of a cDNA coding for human factor IX", Proceedings of the National Academy of Sciences of the USA, (19821101), vol. 79, no. 21, pages 6461 - 6464, XP001318494 | - |
| OPPOSITION | - Kuzmin Dmitry A. А, Et Al, "The clinical landscape for AAV gene therapies", Nature Reviews, (20210301), vol. 20, pages 173 - 174, XP093259697 | - |
| OPPOSITION | - Michael Blaese R, Anderson W French, Culver Kenneth, "Gene therapy", What is biotechnology, (20180101), pages 1 - 12, What is biotechnology, URL: https://www.whatisbiotechnology.org/index.php/science/summary/gene-therapy/, (20240222), XP093133887 | - |
| OPPOSITION | - Nelson David L., Cox Michael M., "Amino Acid Sequence Affects Stability ofthe a Helix", Lehninger Principles of Biochemistry, Fifth Edition, (20070101), pages 119 - 120, XP093259785 | - |
| OPPOSITION | - Shen Ymjiao, Leonard Post, "Viral Vectors and Their Applications", Fields VIROLOGY FIFTH EDITION, Wolters Kluwer, (20070101), pages 539 - 564, XP093259777 | - |
| OPPOSITION | - Shinji et al. Yoshitake, "Nucleotide sequence of the Gene for Human Factor IX (Antihemophilic Factor B)", Biochemistry, (1985), vol. 24, XP001318488 | - |
| OPPOSITION | - Simioni P. et al, "Evidence of the first X-linked thrombophilia due to a novel mutation in clotting factor IX gene resulting in hyperfunctional fix: factor IX arginine 338 leucine (factor IX padua)", abstracts of the XXII Congress of the International Society of Thrombosis and Hemostasis, (20090101), vol. 7, page 1, XP093259692 | - |
| OPPOSITION | - Stryer Lubert, "Biochemistry", Biochemistry, Fourth Edition, W. H. Freeman and Company, (19950101), pages 1 - 25, XP093259534 | - |
| OPPOSITION | - Wallmark Anders et al,, "Polymorphism of normal factor IX detected by mouse monoclonal antibodies", Proc. Natl. Acad. Sci. USA, (19850601), vol. 82, pages 3839 - 3843, XP093259723 | - |
| OPPOSITION | - Wallmark Anders et al, "Population Genetics of the Malmo Polymorphism of Coagulation Factor IX", Hum Hered, (19910101), vol. 41, pages 391 - 396, XP093259625 | - |
| OPPOSITION | - Whitford David, "The frequencies with which amino acid residues occur in proteins", PROTEINS, STRUCTURE AND FUNCTION, Wiley John, Sons, Ltd, (20050101), pages 1 - 17, XP093259746 | - |
| OPPOSITION | - Anson D.S. et al, "The gene structure of human anti-haemophilic factor IX.", The EMBO journal / European Molecular Biology Organization, IRL Press, Oxford, Oxford , (19840501), vol. 3, no. 5, doi:10.1002/j.1460-2075.1984.tb01926.x, ISSN 0261-4189, pages 1053 - 1060, XP093133881 | |
| OPPOSITION | - MIAO C H, ET AL., "INCLUSION OF THE HEPATIC LOCUS CONTROL REGION, AN INTRON, AND UNTRANSLATED REGION INCREASES AND STABILIZES HEPATIC FACTOR IX GENEEXPRESSION IN VIVO BUT NOT IN VITRO", Molecular Therapy, (20000601), vol. 01, no. 06, doi:10.1006/mthe.2000.0075, ISSN 1525-0016, pages 522 - 532, XP001063991 | |
| OPPOSITION | - Lu H. et al, "<mark>Gene therapy for hemophilia B mediated by recombinant adeno</mark>-<mark>associated viral vector with hFIXR338A</mark>, <mark>a high catalytic activity mutation of human coagulation factor IX</mark>", Science China Life Sciences, Science in China Press, (20011201), vol. 44, no. 6, doi:10.1007/bf02879352, ISSN 1006-9305, pages 585 - 592, XP093259629 | |
| OPPOSITION | - YAN JING-BIN ET AL, "Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity", Biochemical Genetics, Springer US, New York, New York, (20060801), vol. 44, no. 7-8, doi:10.1007/s10528-006-9034-1, ISSN 0006-2928, pages 349 - 360, XP002523380 | |
| OPPOSITION | - KYTE J., DOOLITTLE R. F., "A SIMPLE METHOD FOR DISPLAYING THE HYDROPATHIC CHARACTER OF A PROTEIN.", Journal of Molecular Biology, Academic Press, United Kingdom, United Kingdom , (19820505), vol. 157., no. 01., doi:10.1016/0022-2836(82)90515-0, ISSN 0022-2836, pages 105 - 132., XP000609503 | |
| OPPOSITION | - Aucoin, M.G. et al, "Critical assessment of current adeno-associated viral vector production and quantification methods", BIOTECHNOLOGY ADVANCES., ELSEVIER PUBLISHING, BARKING., GB, GB , (20071123), vol. 26, no. 1, doi:10.1016/j.biotechadv.2007.09.001, ISSN 0734-9750, pages 73 - 88, XP022360246 | |
| OPPOSITION | - Xiao Xiao, Makrides S C, "Virus-based vectors for gene expression in mammalian cells: Adeno-associated virus", Gene Transfer and Expression in Mammalian Cells, Elsevier, (20030101), vol. 38, doi:10.1016/S0167-7306(03)38006-8, ISSN 0167-7306, ISBN 978-0-444-51371-7, pages 93 - 108, XP093133891 | |
| OPPOSITION | - HERZOG R W,ET AL, "Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.", Nature Medicine, Nature Publishing Group US, New York, New York, (19990101), vol. 5, no. 1, doi:10.1038/4743, ISSN 1078-8956, pages 56 - 63, XP002242060 | |
| OPPOSITION | - Hasbrouck N C; High K A, "AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects", Gene Therapy, Nature Publishing Group, London, GB, GB , (20080424), vol. 15, no. 11, doi:10.1038/gt.2008.71, ISSN 0969-7128, pages 870 - 875, XP037771869 | |
| OPPOSITION | - SNYDER, R.O. ET AL., "Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors", Nature Genetics, Nature Publishing Group US, New York, New York, (19970716), vol. 16., doi:10.1038/ng0797-270, ISSN 1061-4036, pages 270 - 276., XP002122888 | |
| OPPOSITION | - Perera Lalith, Darden Thomas, Pedersen Lee, "Modeling Human Zymogen Factor IX", Thrombosis and Haemostasis, Schattauer GmbH, DE, DE , (20010401), vol. 85, no. 04, doi:10.1055/s-0037-1615639, ISSN 0340-6245, pages 596 - 603, XP093133909 | |
| OPPOSITION | - GAO G-P,ET AL, "Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.", Proceedings of the National Academy of Sciences (PNAS), National Academy of Sciences, (20020903), vol. 99, no. 18, doi:10.1073/pnas.182412299, ISSN 0027-8424, pages 11854 - 11859, XP002229849 | |
| OPPOSITION | - R A McGraw et al, "Evidence for a prevalent dimorphism in the activation peptide of human coagulation factor IX", Proceedings of the National Academy of Sciences (PNAS), National Academy of Sciences, (19850501), vol. 82, no. 9, doi:10.1073/pnas.82.9.2847, ISSN 0027-8424, pages 2847 - 2851, XP008146066 | |
| OPPOSITION | - ARMENTANO D., ET AL., "EXPRESSION OF HUMAN FACTOR IX IN RABBIT HEPATOCYTES BY RETROVIRUS- MEDIATED GENE TRANSFER: POTENTIAL FOR GENE THERAPY OF HEMOPHILIA B.", Proceedings of the National Academy of Sciences (PNAS), National Academy of Sciences, (19900801), vol. 87., no. 16., doi:10.1073/pnas.87.16.6141, ISSN 0027-8424, pages 6141 - 6145., XP000562786 | |
| OPPOSITION | - BRANDSTETTER HANS ET AL, "X-ray structure of clotting factor IXa: Active site and module structure related to Xase activity and hemophilia B.", Proceedings of the National Academy of Sciences (PNAS), National Academy of Sciences, (19950101), vol. 92, no. 21, doi:10.1073/pnas.92.21.9796, ISSN 0027-8424, pages 9796 - 9800, XP002199692 | |
| OPPOSITION | - WANG L, ET AL, "A factor IX-deficient mouse model for hemophilia B gene therapy", Proceedings of the National Academy of Sciences (PNAS), National Academy of Sciences, (19971001), vol. 94, no. 21, doi:10.1073/pnas.94.21.11563, ISSN 0027-8424, pages 11563 - 11566, XP002278403 | |
| OPPOSITION | - KURACHI S., ET AL., "ROLE OF INTRON I IN EXPRESSION OF THE HUMAN FACTOR IX GENE.", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (19950310), vol. 270., no. 10., doi:10.1074/jbc.270.16.9289, ISSN 0021-9258, pages 5276 - 5281., XP002055415 | |
| OPPOSITION | - CHANG JINLI ET AL, "Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity.", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (19980515), vol. 273, no. 20, doi:10.1074/jbc.273.20.12089, ISSN 0021-9258, pages 12089 - 12094, XP002199691 | |
| OPPOSITION | - MATHUR AKASH, BAJASJ S.P., "Protease and EGF1 domains of factor IXa play distinct roles in binding to factor VIIIa. Importance of helix 330 (helix 162 in chymotrypsin) of protease domain of factor IXa in its interaction with factor VIIIa", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (19990625), vol. 274, no. 26, doi:10.1074/jbc.274.26.18477, ISSN 0021-9258, pages 18477 - 18486, XP002523381 | |
| OPPOSITION | - Bajaj S. Paul et al, "Factor IXa:Factor VIIIa Interaction", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20010501), vol. 276, no. 19, doi:10.1074/jbc.M011680200, ISSN 0021-9258, pages 16302 - 16309, XP093133908 | |
| OPPOSITION | - Wang Lili et al, "Cross-Presentation of Adeno-Associated Virus Serotype 2 Capsids Activates Cytotoxic T Cells But Does Not Render Hepatocytes Effective Cytolytic Targets", HUMAN GENE THERAPY, Mary Ann Liebert, Inc. Publishers, GB, GB , (20070301), vol. 18, no. 3, doi:10.1089/hum.2007.001, ISSN 1043-0342, pages 185 - 194, XP093133900 | |
| OPPOSITION | - GIANNELLI F ET AL, "HEMOPHILIA B DATABASE OF POINT MUTATIONS AND SHORT ADDITIONS AND DELETIONS", Nucleic Acids Research, Oxford University Press, GB, GB , (19900101), vol. 18, no. 14, doi:10.1093/nar/18.14.4053, ISSN 0305-1048, pages 4053 - 4060, XP002774525 | |
| OPPOSITION | - Wallmark A. et al, "Determination of factor IX allotypes for carrier identification in haemophilia B", British Journal of Haematology, John Wiley, Hoboken, USA, Hoboken, USA, (19871201), vol. 67, no. 4, doi:10.1111/j.1365-2141.1987.tb06164.x, ISSN 0007-1048, pages 427 - 432, XP093259729 | |
| OPPOSITION | - Lambert T. et al, "® : efficacy and safety in previously treated patients with moderately severe to severe haemophilia B", HAEMOPHILIA, BLACKWELL SCIENCE, OXFORD, GB, GB , (20070501), vol. 13, no. 3, doi:10.1111/j.1365-2516.2007.01458.x, ISSN 1351-8216, pages 233 - 243, XP093259790 | |
| OPPOSITION | - Hough C., Lillicrap D., "Gene therapy for hemophilia: an imperative to succeed : Gene therapy for hemophilia", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, GB , (20050601), vol. 3, no. 6, doi:10.1111/j.1538-7836.2005.01401.x, ISSN 1538-7933, pages 1195 - 1205, XP055788976 | |
| OPPOSITION | - BOWIE J U, ET AL., "DECIPHERING THE MESSAGE IN PROTEIN SEQUENCES: TOLERANCE TO AMINO ACID SUBSTITUTIONS", Science, American Association for the Advancement of Science, US, US , (19900316), vol. 247, doi:10.1126/science.2315699, ISSN 0036-8075, pages 1306 - 1310, XP002925326 | |
| OPPOSITION | - Federico Mingozzi et al, "Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer", The Journal of Clinical Investigation, B M J Group, (20030501), vol. 111, no. 9, doi:10.1172/JCI16887, pages 1347 - 1356, XP055738051 | |
| OPPOSITION | - Manno C. S. et al, "AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B", Blood, W.B. Saunders, AMSTERDAM, NL, AMSTERDAM, NL, (20030415), vol. 101, no. 8, doi:10.1182/blood-2002-10-3296, ISSN 0006-4971, pages 2963 - 2972, XP093133892 | |
| OPPOSITION | - SABATINO DENISE E ET AL, "Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene", Blood, W.B. Saunders, AMSTERDAM, NL, AMSTERDAM, NL, (20041101), vol. 104, no. 9, doi:10.1182/blood-2004-03-1028, ISSN 0006-4971, pages 2767 - 2774, XP002555908 | |
| OPPOSITION | - SCHUETTRUMPF JOERG ET AL, "Factor IX variants improve gene therapy efficacy for hemophilia B", Blood, W.B. Saunders, AMSTERDAM, NL, AMSTERDAM, NL, (20050315), vol. 105, no. 6, doi:10.1182/blood-2004-08-2990, ISSN 0006-4971, pages 2316 - 2323, XP002555907 | |
| OPPOSITION | - Samelson-Jones Benjamin et al, "Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants", Blood Advances, American Society of Hematology, (20210309), vol. 5, no. 5, doi:10.1182/bloodadvances.2019000405, ISSN 2473-9529, pages 1324 - 1332, XP093107954 | |
| OPPOSITION | - MOUNT J D , ET AL, "Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy", Blood, W.B. Saunders, AMSTERDAM, NL, AMSTERDAM, NL, (20020415), vol. 99, no. 8, doi:10.1182/blood.V99.8.2670, ISSN 0006-4971, pages 2670 - 2676, XP002312777 | |
| OPPOSITION | - Brownlee G. G., "The Molecular Genetics of Haemophilia A and B", Journal of Cell Science, Co. of Biologists, England, England, (19860101), vol. 1986, no. Supplement_4, doi:10.1242/jcs.1986.Supplement_4.24, ISSN 0021-9533, pages 445 - 458, XP093133902 | |
| OPPOSITION | - Bezemer I. D. et al, "F9 Malmo, factor IX and deep vein thrombosis", Haematologica, (20090501), vol. 94, no. 5, doi:10.3324/haematol.2008.003020, ISSN 0390-6078, pages 693 - 699, XP093133910 | |
| SEARCH | - Graham J B ET AL, "The Malmö polymorphism of coagulation factor IX, an immunologic polymorphism due to dimorphism of residue 148 that is in linkage disequilibrium with two other F.IX polymorphisms", American journal of human genetics, United States, (19880401), pages 573 - 580, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1715231/pdf/ajhg00127-0049.pdf, (20220616), XP055932218 [A] 1-6 * abstract * | - |
| SEARCH | - KURACHI K ET AL, "Isolation and characterization of a cDNA coding for human factor IX", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, (19821201), vol. 79, doi:10.1073/PNAS.79.21.6461, ISSN 0027-8424, pages 6461 - 6464, XP002135656 [Y] 3 * figure 2 * | |
| SEARCH | - GIANNELLI F ET AL, "HEMOPHILIA B DATABASE OF POINT MUTATIONS AND SHORT ADDITIONS AND DELETIONS", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, GB, (19900101), vol. 18, no. 14, doi:10.1093/NAR/18.14.4053, ISSN 0305-1048, pages 4053 - 4060, XP002774525 [A] 1-6 * the whole document * | |
| SEARCH | - SCHUETTRUMPF JOERG ET AL, "Factor IX variants improve gene therapy efficacy for hemophilia B", BLOOD, (20050315), vol. 105, no. 6, ISSN 0006-4971, pages 2316 - 2323, XP002555907 [A] 1-6 * the whole document * | |
